Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of MIRCERA is substantial. |
Clinical Added Value
| no clinical added value |
MIRCERA offers no improvement in actual benefit (level V) compared to the other
erythropoiesis-stimulating agents that are indicated in the correction of anaemia associated with chronic kidney disease. |
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
ukXxmXAQsm3CkLTU
